Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea (Q35640492)

9 August 2017

Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea (English)

1 reference

Helicobacter pylori infectious disease

9 August 2017

1 reference

1 reference

Seung Young Kim

1

1 reference

9 August 2017

Sung Woo Jung

2

1 reference

9 August 2017

Jeong Han Kim

3

1 reference

9 August 2017

Ja Seol Koo

4

1 reference

9 August 2017

Hyung Joon Yim

5

1 reference

9 August 2017

Jong Jae Park

6

1 reference

9 August 2017

Hoon Jai Chun

7

1 reference

9 August 2017

Sang Woo Lee

8

1 reference

9 August 2017

Jai Hyun Choi

9

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

British Journal of Clinical Pharmacology

9 August 2017

1 reference

9 August 2017

73

1 reference

9 August 2017

1

1 reference

9 August 2017

140-143

1 reference

New concepts of resistance in the treatment of Helicobacter pylori infections

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248264

Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248264

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248264

Evaluation of the safety of macrolides

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248264

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248264

Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248264

A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

27 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04048.X

Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04048.X

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04048.X

Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04048.X

High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248264

pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism

25 September 2018

1 reference

12 December 2020

Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers

1 reference

12 December 2020

Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens

1 reference

12 December 2020

Dose-response relationship of lansoprazole to gastric acid antisecretory effects

1 reference

12 December 2020

Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form

1 reference

12 December 2020

Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy

1 reference

12 December 2020

Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy

1 reference

12 December 2020

10.1111/J.1365-2125.2011.04048.X

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference